MENA Fabry Disease Treatment Market Expected to Reach USD 295.32 Million by 2034, Growing at a CAGR of 5.8%
Global MENA Fabry Disease Treatment Market size and share is currently valued at USD 167.76 million in 2024 and is anticipated to generate an estimated revenue of USD 295.32 million by 2034, according to the latest study by Polaris Market Research. Besides, the report notes that the market exhibits a robust 5.8% Compound Annual Growth Rate (CAGR) over the forecasted timeframe, 2025 – 2034
Market Definition
The MENA Fabry Disease Treatment Market focuses on the diagnosis and management of Fabry disease across Middle East and North African countries, including Saudi Arabia, UAE, Egypt, and Morocco. Characterized by progressive damage to vital organs due to the buildup of globotriaosylceramide, Fabry disease necessitates specialized treatment regimens like enzyme replacement therapy (ERT), pharmacological chaperones, and emerging gene therapies. This market is influenced by increasing government healthcare investments, improved access to genetic testing, and rising awareness among medical professionals in the region. Cross-border partnerships between global biopharma companies and local healthcare entities have also contributed to improved drug availability. Challenges such as cultural barriers, underdiagnosis, and limited specialized care infrastructure persist but are gradually being addressed through medical training programs and telemedicine initiatives. Furthermore, regulatory incentives for orphan drugs and increasing prevalence data collection are supporting market growth. With an expanding patient base and technological advancements in precision medicine, the MENA region holds significant potential for development in Fabry disease therapeutics over the coming decade.
Key Report Highlights
- The report highlights the key region that accounts for the highest revenue share in the global MENA Fabry Disease Treatment market.
- It identifies the leading country within this region that makes a significant contribution to the market’s overall performance.
- The report outlines the dominant segment that holds a major share of the market.
- It also emphasizes the fastest-growing segment projected to gain strong traction during the forecast period.
- Qualitative and quantitative market analysis have been used to provide an in-depth understanding of the market.
Market Overview: Key Figures at a Glance
Market Size in 2024 – USD 167.76 million
Market Size in 2025 – USD 77.46 million
Revenue Forecast by 2034 – USD 295.32 million
CAGR – 5.8% from 2025 to 2034
Get access to the full report or request a complimentary sample for in-depth analysis:
Market Growth Drivers
Key growth drivers in the MENA Fabry Disease Treatment Market include increasing healthcare investments, expanded newborn screening programs, and rising awareness of lysosomal storage disorders. Countries like the UAE and Saudi Arabia are prioritizing early genetic diagnostics and subsidized access to enzyme replacement therapies (ERT). Government-backed initiatives and international pharmaceutical partnerships enhance therapeutic availability. Improved patient advocacy, digital health tools, and specialist training have helped reduce underdiagnosis rates. Furthermore, favorable regulatory frameworks and inclusion of rare disease medications in national formularies are accelerating market development. The shift toward precision medicine and telehealth consultations is also supporting long-term treatment adherence.
Market Key Players
The competitive landscape features a mix of long-standing companies and emerging contenders. MENA Fabry Disease Treatment Market Leading players are actively pursuing R&D initiatives and strategic moves to strengthen their market position. Notable participants include
- Chiesi Farmaceutici S.p.A.
- JCR Pharmaceuticals Co., Ltd.
- Protalix BioTherapeutics Inc.
- Sanofi
- Takeda Pharmaceutical
- Amicus Therapeutics, Inc.
- Idorsia Pharmaceuticals Ltd.
- Idorsia Pharmaceuticals Ltd.
- ISU ABXIS Co., Ltd.
- Sangamo Therapeutics, Inc.
